Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Timothy Ko

Interventional Pain Medicine Erie, PA Medical Doctor

NPI 1285847699 CMS profile 58142

2374 Village Common Dr Ste 100, Erie, PA 16506

Open in the dashboard

General payments

$7,028

229 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Timothy Ko of Erie, PA is reported in the CMS Open Payments database as having received $7,028 across 229 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 65th percentile of Interventional Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $353 9
2024 General $146 8
2023 General $1,663 26
2022 General $804 28
2021 General $490 15
2020 General $475 25
2019 General $3,097 118

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Timothy Ko
  • Interventional Pain Medicine median
  • Middle half of Interventional Pain Medicine
  • National median

In program year 2025, general payments to Timothy Ko were reported at $353. Among 1,891 Interventional Pain Medicine profiles paid that year, the median was $657 and the middle half received between $184 and $1,753.

Show as a table
Year Timothy Ko Interventional Pain Medicine median Middle half National median
2019 $3,097 $684 $216–$2,079 $163
2020 $475 $382 $122–$1,109 $114
2021 $490 $552 $167–$1,554 $132
2022 $804 $605 $187–$1,924 $149
2023 $1,663 $671 $195–$1,915 $160
2024 $146 $684 $206–$1,837 $164
2025 $353 $657 $184–$1,753 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $4,724 97 payments
  2. Daiichi Sankyo Inc. $390 44 payments
  3. Saluda Medical Americas, Inc. $320 3 payments
  4. Scilex Pharmaceuticals Inc. $267 17 payments
  5. Nevro Corp. $211 3 payments
  6. TerSera Therapeutics LLC $148 8 payments
  7. Abbott Laboratories $123 6 payments
  8. Teva Pharmaceuticals USA, Inc. $106 8 payments
  9. Sentynl Therapeutics, Inc. $87 5 payments
  10. Curonix LLC $72 3 payments
  11. Other $580 35 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,817 224 payments
  2. Travel and Lodging $1,211 5 payments
Products named General payments · program years 2019–2025
  1. SPECTRA WAVEWRITER $1,774 24 payments
  2. General - Pain Management $606 17 payments
  3. Morphabond ER $390 44 payments
  4. WaveWriter Alpha Prime 16 $330 9 payments
  5. Evoke SCS $320 3 payments
  6. GENERAL PAIN MANAGEMENT $232 12 payments
  7. General - Therapies $210 3 payments
  8. ZTLido $159 10 payments
  9. PRIALT $148 8 payments
  10. Superion $141 2 payments
  11. Other $1,670 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

1,686

Median for Interventional Pain Management: 1,220

Drug cost

$26,592

Median for Interventional Pain Management: $39,344

Branded share of claims

31.7%

Median for Interventional Pain Management: 34.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 264 $6,041
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 234 $4,534
Gabapentin Generic 348 $3,879
Celecoxib Generic 75 $1,949
Pregabalin Generic 84 $1,608
Oxycodone Hcl Generic 71 $1,383
Lidocaine Hcl Generic 13 $1,193
Tizanidine Hcl Generic 105 $1,049
Tramadol Hcl Generic 151 $745
Lidocaine Generic 12 $741

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,476 Part D prescribers listed as Interventional Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 34 billing codes

Paid by Medicare

$89,637

Medicare's payments for the services billed

Medicare patients

378

Average age 74

Services billed

1,178

202 women, 176 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 75%
Ischemic heart disease 33%
Depression 30%
Diabetes 29%
Chronic kidney disease 26%
Osteoporosis 19%
COPD 17%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

229 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Interventional Pain Medicine in Pennsylvania

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record